Skip to main content
OpenTrials
Completed

NCT Number: NCT01348399

Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)

The objective of this study is to evaluate effectiveness and safety of XIENCE PRIME stent in the "real world" daily practice as compared with other drug eluting stents (DESs)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Hallym University Sacred Heart Hospital, Anyang, South Korea

Loading trial locations.

About this study

This study is a non-randomized, prospective, open-label registry to compare the effectiveness and safety of XIENCE PRIME stents versus other DESs in patients with coronary artery disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients receiving XIENCE PRIME stents.
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion criteria

  • Patients with a mixture of other DESs
  • Terminal illness with life expectancy <1 year
  • Patients presented with cardiogenic shock

Treatment and study plan

Primary outcomes

  1. composite of death, nonfatal myocardial infarction (MI), or target- Vessel Revascularization (TVR)

    Time frame: 12 months post procedure

Secondary outcomes

  1. Death (all cause and cardiac)

    Time frame: one month

  2. Death (all cause and cardiac)

    Time frame: 6 months

  3. Death (all cause and cardiac)

    Time frame: yearly up to 5 years

  4. MI

    Time frame: one month

  5. MI

    Time frame: 6 months

  6. MI

    Time frame: yearly up to 5 years

  7. Composite of death or MI

    Time frame: one month

  8. Composite of death or MI

    Time frame: 6 months

  9. Composite of death or MI

    Time frame: yearly up to 5 years

  10. Composite of cardiac death or MI

    Time frame: one month

  11. Composite of cardiac death or MI

    Time frame: 6 months

  12. Composite of cardiac death or MI

    Time frame: yearly up to 5 years

  13. TVR

    Time frame: one month

  14. TVR

    Time frame: 6 months

  15. TVR

    Time frame: yearly up to 5 years

  16. Target-lesion revascularization (TLR)

    Time frame: one month

  17. Target-lesion revascularization (TLR)

    Time frame: 6 months

  18. Target-lesion revascularization (TLR)

    Time frame: yearly up to 5 years

  19. Stent thrombosis (ARC criteria)

    Time frame: one month

  20. Stent thrombosis (ARC criteria)

    Time frame: 6 months

  21. Stent thrombosis (ARC criteria)

    Time frame: yearly up to 5 years

  22. Procedural success (defined as achievement of a final diameter stenosis of <30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization)

    Time frame: At discharge from the index hospitalization

Sponsors and collaborators

Lead sponsor

Seung-Jung Park

Other

Collaborators

  • Abbott
  • CardioVascular Research Foundation, Korea

Registry information

Official study title

Evaluation of Effectiveness and Safety of XIENCE PRIME™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Important dates

Study start
2011
Primary completion
2014
Study completion
2017
First posted
May 5, 2011
Registry last updated
Jun 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.